Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6,216 JPY | -0.24% | -2.51% | -11.85% |
Mar. 22 | BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug | MT |
Mar. 22 | Lifenet to Launch Dementia-Focused Insurance Product in April | MT |
Business Summary
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Number of employees: 11,076
Sales per Business
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
91.9
%
| 626,281 | 82.8 % | 684,434 | 91.9 % | +9.29% |
Other
8.1
%
| 129,945 | 17.2 % | 59,969 | 8.1 % | -53.85% |
Sales per region
JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Japan
33.6
%
| 243,385 | 32.2 % | 250,327 | 33.6 % | +2.85% |
Americas
32.1
%
| 226,719 | 30.0 % | 239,293 | 32.1 % | +5.55% |
China
14.6
%
| 106,592 | 14.1 % | 108,562 | 14.6 % | +1.85% |
Europe
11.6
%
| 126,745 | 16.8 % | 86,026 | 11.6 % | -32.13% |
Other
8.1
%
| 52,784 | 7.0 % | 60,195 | 8.1 % | +14.04% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
Yasushi Okada
COO | Chief Operating Officer | 65 | 81-03-31 |
Yosuke Akita
CMP | Compliance Officer | 59 | 89-03-31 |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 88-03-31 |
Hideki Hayashi
BRD | Director/Board Member | 66 | 81-03-31 |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 82-03-31 |
Masatomi Akana
IRC | Investor Relations Contact | 57 | 90-03-31 |
Sayoko Sasaki
IRO | Public Communications Contact | 55 | 91-03-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 21-05-31 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
Hideki Hayashi
BRD | Director/Board Member | 66 | 81-03-31 |
Yuko Yasuda
BRD | Director/Board Member | 62 | - |
Yoshiteru Kato
BRD | Director/Board Member | 64 | 88-03-31 |
Hideyo Uchiyama
BRD | Director/Board Member | 71 | 18-05-31 |
Yumiko Miwa
BRD | Director/Board Member | 58 | 20-05-31 |
Director/Board Member | 59 | 22-06-16 | |
Hiroyuki Kato
BRD | Director/Board Member | 66 | 82-03-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 296,566,949 | 278,292,621 ( 93.84 %) | 9,530,708 ( 3.214 %) | 93.84 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
EISAI CO., LTD. 3.21% | 9,530,200 | 3.21% | 398,221,885 $ |
MATSUKIYOCOCOKARA & CO. 1.97% | 8,445,000 | 1.97% | 139,988,289 $ |
474,000 | 0.96% | 10,751,856 $ | |
ROIVANT SCIENCES LTD. 0.11% | 874,957 | 0.11% | 10,009,508 $ |
COGSTATE LIMITED 6.85% | 11,738,243 | 6.85% | 9,554,226 $ |
VITAL KSK HOLDINGS, INC. 1.24% | 642,154 | 1.24% | 5,697,736 $ |
349,000 | 0.43% | 3,215,546 $ | |
546,005 | 2.24% | 2,918,446 $ | |
134,748 | 0.06% | 2,039,631 $ | |
56,608 | 0.14% | 180,788 $ |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Eisai Ltd. (United Kingdom)
Eisai Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Eisai Ltd. (United Kingdom) is a pharmaceutical company based in Hatfield, UK. Part of Eisai Co., Ltd., Eisai Ltd. prioritizes patients and their families by continually improving the benefits that healthcare can provide. The British company was founded in 1988 and Gary Bryan Hendler has been the CEO of the company since 2008. |
Pharmaceuticals: Major
|
Eisai Pharmaceuticals India Pvt Ltd.
Eisai Pharmaceuticals India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Pharmaceuticals India Pvt Ltd. is an Indian company that manufactures and exports drug substances. The private company is based in Visakhapatnam, India. The company was founded in 2007. The CEO is Sanjit Singh Lamba. |
Pharmaceuticals: Major
|
Eisai Manufacturing Ltd.
Eisai Manufacturing Ltd. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., Eisai Manufacturing Ltd. is a pharmaceutical company based in Hatfield, UK. The British company's focus is on developing new medicines for neglected tropical diseases and malaria, improving access to medicines for non-communicable diseases, and promoting sustainability. Eisai Manufacturing is committed to funding the 3rd phase of health innovative technology fund activities. The private company's official corporate website provides information on their initiatives and HHC concept. |
Pharmaceuticals: Major
|
Sector
Sales per Business
Sales per region
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.85% | 11.81B | |
+33.46% | 701B | |
+26.24% | 570B | |
+0.93% | 381B | |
+21.03% | 334B | |
+17.51% | 322B | |
+0.74% | 209B | |
+2.95% | 212B | |
-6.05% | 205B | |
-3.61% | 157B |
- Stock
- Equities
- Stock Eisai Co., Ltd. - Japan Exchange
- Company Eisai Co., Ltd.